Connect with Decision Makers in MASH
The 9th MASH Drug Development Summit offers an unparalleled platform to connect directly with 60+ senior leaders and pioneering drug development experts driving innovation in MASH therapeutics.
What to Expect?
Gain unparalleled brand visibility and reach a highly focused audience of 60+ senior leaders from top biopharma companies actively involved in MASH drug development
Showcase your innovative solutions and position your company as a thought leader in the cutting-edge field of MASH therapeutics and highlight your offerings to the only summit dedicated to MASH
Gain valuable market insights and stay ahead of the curve by gaining exclusive access to the latest scientific advancements, emerging technologies, and critical trends shaping the future of MASH therapies, from novel mechanisms of action and non-invasive diagnostics to combination strategies
Forge strategic partnerships and engage in meaningful discussions and identify synergistic opportunities with leading organizations, including Madrigal Pharmaceuticals, Eli Lilly, Takeda Pharmaceuticals, Ridgeline Therapeutics, and 89 Bio, to accelerate innovation and expand your reach within the MASH therapeutics market
Key Interest Areas:
Preclinical Modelling
Advanced in vitro and in vivo MASH models that accurately replicate human disease progression, including steatosis, inflammation, and fibrosis, and provide predictive insights into therapeutic response, enabling the identification of novel targets and mechanism-of-action validation for new drug candidates
Biomarkers & Diagnostic
(Non-Invasive Biomarkers)
Novel, validated non-invasive biomarkers for MASH diagnosis, disease progression monitoring, and treatment response assessment, capable of differentiating disease stages, predicting long-term outcomes, and serving as surrogate endpoints for regulatory approval, to reduce reliance on liver biopsy and facilitate patient stratification
Clinical CROs
Clinical Research Organizations (CROs) with deep expertise in MASH clinical trial design, patient recruitment for diverse MASH populations (including specific fibrosis stages), and efficient execution of studies focusing on histological and non-invasive endpoints. This industry also seeks CROs capable of specialized pathology review, advanced data analytics for complex endpoint assessment, and robust patient retention strategies for long-term outcome studies
Attending Companies Include:
Any questions? Curious to know more about the range of partnership opportunities? Want to understand what your partnership with Hanson Wade could look like?
Get In Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Karim Hoceine
Partnerships Director